These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25956727)

  • 1. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
    BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.].
    Alcántara A; Cózar JM; Errando C; Rubio-Rodríguez D; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A
    Arch Esp Urol; 2018 Sep; 71(7):595-606. PubMed ID: 30198851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
    van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
    Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
    Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
    BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
    Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
    BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.
    Drake MJ; Oelke M; Snijder R; Klaver M; Traudtner K; van Charldorp K; Bongaerts D; Van Kerrebroeck P
    PLoS One; 2017; 12(2):e0170726. PubMed ID: 28166296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis.
    Li MC; Wang ZY; Yang J; Guo XL; Wang T; Wang SG; Liu JH; Ye ZQ
    Asian J Androl; 2015; 17(1):124-34. PubMed ID: 25337836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Dimitropoulos K; Gravas S
    Drug Des Devel Ther; 2015; 9():1707-16. PubMed ID: 25834406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamsulosin/solifenacin fixed-dose combination tablet for the treatment of male lower urinary tract symptoms.
    Romancik M; Pandian S; Drake MJ
    Drugs Today (Barc); 2014 Dec; 50(12):803-11. PubMed ID: 25588085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with tamsulosin and solifenacin for male lower urinary tract symptoms with predominant filling symptoms: a new approach to an old problem.
    Angulo JC
    Curr Med Res Opin; 2015 Nov; 31(11):1963-5. PubMed ID: 26368336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.
    Gong M; Dong W; Huang G; Gong Z; Deng D; Qiu S; Yuan R
    Curr Med Res Opin; 2015; 31(9):1781-92. PubMed ID: 26211817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Hakimi Z; Herdman M; Pavesi M; Devlin N; Nazir J; Hoyle C; Odeyemi IA
    Qual Life Res; 2017 May; 26(5):1187-1195. PubMed ID: 27896711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin.
    Yang PS; Chen CL; Hou CP; Lin YH; Tsui KH
    Clin Interv Aging; 2018; 13():235-242. PubMed ID: 29445269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.